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Abstract

Research Question

Discussion

Cystic fibrosis is an autosomal recessive genetic disorder that
severely affects the lungs as well as other organs in the body. The
pathophysiology of cystic fibrosis lung disease involves the
production of thick and sticky mucus that accumulates leading to
obstruction and inflammation of the airways. This disease is
characterized by abnormal transport of sodium and chloride across
an epithelium by defective genes, resulting in thick mucus
secretions.
Nebulized hypertonic saline (3% NaCl) improves mucociliary
clearance through rehydration of the airway surface liquid of the
lungs. The purpose of this study is to evaluate the effects of
nebulized hypertonic saline in improving lung function and
decreasing exacerbation rates in older children (10-18 years of
age) and adults with stable cystic fibrosis compared to normal
saline (0.9%).

In older children and adults with stable cystic fibrosis who have
failed to show improvement with recombinant human
deoxyribonuclease (rhDNase) does treatment with nebulized
hypertonic saline improve lung function, forced expiatory
volume in one second (FEV1) and pulmonary exacerbation
compared to NS?

 In a controlled long-term trial, treatment with hypertonic saline
for one year had an adequate yet continued improvement in the
level of lung function.
 More interesting, however, were the apparent reduction rates of
exacerbations, antibiotic use, and overall improvement of
quality of life that were associated with use of hypertonic
saline.

The review of literature will focus on comparing the use of
nebulized hypertonic saline in enhancing mucociliary clearance in
CF patients compared to other methods. The expected outcome is
that nebulized hypertonic saline treatment will improve lung
function and decrease exacerbation of CF in these groups.

Introduction
 Cystic fibrosis characterized by abnormal transport of sodium and
chloride across an epithelium by defective genes, resulting in thick
mucus secretions.
 Enhancement of therapy practices to advance outcomes is an area of
cystic fibrosis care, which has progressed significantly over the last
few decades. As the choices of treatment for CF increases, the
clinicians are confronted with the predicament of developing a
treatment plan that provides optimal benefit, addresses the complex
therapeutic routine on patient compliance and is cost effective.

Literature Review
Gupta et al. (2012) conducted a randomized control trial in
which 31 children diagnosed with cystic fibrosis were
administered either 3% saline or 7% saline for 28 days.
 Peak expiratory flow rate improved from 172.7 l/min at a
baseline to 195.3 l/min on day 28 of the trial in the group
that received the 3% hypertonic saline and from 194l/min
to 212 l/min in the group that received the 7% saline.

Eng et al. (1996) conducted a 48 week double-blind study in

 Eng et al. (1996) observed improvement of 15% in FEV1 from
baseline with 6% hypertonic saline compared to isotonic saline..
 Hypertonic saline treatment is inexpensive and safe as an
additional therapy in patients with cystic fibrosis and can play
an essential role in the clinical setting.

Figure 2

Nebulized hypertonic saline illustrates tangible improvement in
mucus clearance without major adverse effects by reducing the
number of exacerbation, use of antibiotics, and improving lung
function.
Hypertonic saline achieves this function by its direct effect on
mucus, breaking the ionic bonds leading to lower viscosity and
elasticity.
Hypertonic saline has been shown to improve mucociliary
clearance in patients with cystic fibrosis and recent studies
provide indication for clinical efficacy for hypertonic saline in
cystic fibrosis.
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Figure 1

 Today, CF patients are living longer and clinicians need to recognize
and implement early treatment to maintain optimal outcome. An
early efficient management of children with CF is a road map to
increasing the quality of life and health status of these patients as
they transition to adulthood.
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